drugset
drugset / Trial / NCT07033819

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

NCT07033819 ↗

Phase 2 Recruiting 48 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

In this study, investigators propose to use fuzuloparib and apatinib as neoadjuvant therapy for Homologous recombination deficiency （HRD）positive advanced ovarian cancer patients, aiming to explore the efficacy and safety of this 'de-chemotherapy' regimen as neoadjuvant therapy for advanced ovarian cancer, and to conduct genetically related subgroup analyses, to guide the precision therapy and provide a new therapeutic option for HRD-positive patients with advanced ovarian cancer. To provide a new treatment option In order to increase the R0 resection rate of surgery and reduce chemotherapy resistance, thus improving the prognosis and prolonging the survival of patients.

Timeline

Start
2025-06-25
Primary completion
2027-06-20
Completion
2028-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluzoparib Small molecule 150 mg Oral
Subject Rivoceranib Small molecule 250 mg Oral
Background Carboplatin Small molecule 4 unknown Intravenous
Background Carboplatin Small molecule 5 unknown Intravenous
Background Paclitaxel Small molecule 150 mg/m2 Intravenous
Background Paclitaxel Small molecule 175 mg/m2 Intravenous

Indications

ovarian carcinoma